<DOC>
	<DOCNO>NCT00175435</DOCNO>
	<brief_summary>This study look happen level protection hepatitis B ( HB ) disease 'helper ' gel apply skin injection site small dose hepatitis B vaccine .</brief_summary>
	<brief_title>Optimizing Hepatitis B Vaccine Response Through Use Topical Immune Modulator</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>Previously vaccinate conventional hepatitis B vaccine series 10 year ago Generally healthy Is free HB disease and/or negative core antibody Known seroconverted positive vaccine series ( without extra dos ) Speaks understand English adequately Available 4 visit within designate timeline ( 30 day ) No allergy HB vaccine components No blood blood component within previous 6 month Not pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Topical Immune Modulator</keyword>
	<keyword>resiquimod gel</keyword>
	<keyword>Hepatitis B booster response</keyword>
	<keyword>Vaccine Evaluation</keyword>
	<keyword>Prevention Hepatitis B disease</keyword>
</DOC>